SCHEMBL4159295

SCHEMBL4159295

NC(=O)c1ccc(Oc2ccc(Cl)cc2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.54
F2 P00734 1/20 0.52
CCNC P24863 9/20 0.49
CDK8 P49336 9/20 0.49
CCNT1 O60563 2/20 0.49
CDK9 P50750 2/20 0.49
ICAM1 P05362 1/20 0.49
SELE P16581 1/20 0.49
VCAM1 P19320 1/20 0.49
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
PARP15 Q460N3 1/20 0.40
PARP14 Q460N5 1/20 0.40
PARP10 Q53GL7 1/20 0.40
PARP16 Q8N5Y8 1/20 0.40
PARP11 Q9NR21 1/20 0.40
PARP4 Q9UKK3 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155072 0.83 ICAM1 (0.49) F2CCNCCDK8ICAM1SELE
SCHEMBL4144009 0.83 PARP10 (0.50) IKBKBF2CCNCCDK8ICAM1
SCHEMBL4156126 0.81 ICAM1 (0.54) IKBKBF2ICAM1SELEVCAM1
SCHEMBL4964117 0.81 PARP10 (0.57) IKBKBF2ICAM1SELEALDH1A1
SCHEMBL6633394 0.77 PARP10 (0.58) F2CCNCCDK8ALDH1A1KMT2A
SCHEMBL14132132 0.76 HRH3 (0.47)
SCHEMBL4161369 0.73 CYP3A4 (0.42) IKBKBF2ICAM1SELEVCAM1
SCHEMBL4148474 0.72 CDK1 (0.54) F2ICAM1SELEVCAM1KMT2A
SCHEMBL4155387 0.72 ICAM1 (0.54) F2ICAM1SELEVCAM1RAB9A
SCHEMBL1989785 0.71 PARP10 (0.79) F2ALDH1A1KMT2APARP15PARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD IKBKB 3079/4885F2 2651/4885CCNC 2203/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 IKBKB 4308/4885F2 1635/4885CCNC 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.